Enzyvant focuses on innovative treatments, science, and technology to address patient needs in psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Self-described as an innovation growth engine, the company aims to improve patient outcomes.

Enzyvant

Google Font API

Cloudflare CDN

Person Schema

Cloudflare

Gravatar Profiles

Chief Medical Officer

Howard Lazarus

SVP, Platform Head for T-Cell Generation

Andrea Ashford-Hicks

Vice President Finance

Fabien VIAL

VP, Clinical Development

Jill Denning

Senior Vice President, Business Operations

Jim Bishop

Principal

Jim Luterman

Vice President of Pharmaceutical Development & Manufacturing

Larry Weiner

Director, Translational Science

Abhishek Das

Senior Director, Quality Operations

Anthony Castellazzo

Associate Director, CMC Manufacturing

Brittny Pulley

Judy Chuk

VP of Strategy and Operations

Johanna Rossell

Chief Commercial Officer

Beth Anne Lang

Senior Vice President, Regulatory Affairs & Pharmacovigilance

Bill Symonds

Health Care Acquired Companies With Fewer Than 100 Employees

Europe, Middle East, and Africa (EMEA) Biotechnology Companies (Top 10K)

Switzerland Companies that Exited

Private Basel-Stadt Companies

Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.

Basel

Basel-Stadt

Switzerland

Europe

Enzyvant Sciences

Roivant receives bad news — and so does Softbank

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 29, 2024 5:24 PM	1994e310
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 29, 2024 5:24 PM	ee782e63
crunchbase trigger	general	Nov 11, 2024 10:30 AM	f12bb90c
crunchbase profile	general	Nov 12, 2024 8:54 AM	5b0ba26d
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 9:06 AM	9731bfbb
peers	general	Sep 29, 2024 5:24 PM	2d5b8119
news basic	general	Sep 29, 2024 5:24 PM	c3be5567
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ENZYVANT

Enzyvant